Cookson Peirce & Co. Inc. Invests $1.72 Million in Adaptive Biotechnologies Corporation $ADPT

Cookson Peirce & Co. Inc. bought a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 105,689 shares of the company’s stock, valued at approximately $1,716,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADPT. EverSource Wealth Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the period. Assetmark Inc. boosted its stake in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares during the period. Clearstead Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 1,545.6% during the 4th quarter. Clearstead Advisors LLC now owns 3,752 shares of the company’s stock worth $61,000 after acquiring an additional 3,524 shares during the period. Finally, Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $93,000. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. TD Cowen lifted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Adaptive Biotechnologies Price Performance

ADPT opened at $16.90 on Monday. The business has a fifty day simple moving average of $14.17 and a 200 day simple moving average of $15.62. The company has a market capitalization of $2.70 billion, a PE ratio of -51.21 and a beta of 2.15. Adaptive Biotechnologies Corporation has a 1 year low of $9.90 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) EPS. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 37,263 shares of the business’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total value of $566,024.97. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at $33,122,068.42. The trade was a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kyle Piskel sold 3,115 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the sale, the chief financial officer owned 256,725 shares of the company’s stock, valued at $3,347,694. This trade represents a 1.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,740,155 shares of company stock worth $23,468,600 in the last ninety days. 5.70% of the stock is owned by company insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.